Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-27

FDA Approved: EVRYSDI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Evrysdi (risdiplam) from Genentech, expanding the approved labeling for the drug. This action represents an upda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EVRYSDI (risdiplam)

Snippet

SUPPL AP for EVRYSDI (RISDIPLAM)